Elara Pharma Raises €4.6 Million
Elara Pharmaceuticals GmbH, a Heidelberg, Germany-based developer of Hypoxia Inducible Factor (HIF) antagonizing drugs for treating cancer, has raised €2.6 million in Series A funding led by EMBL Ventures. The round also triggered an additional €2 million investment from the BMBF GOBio and the Biotechnologie Rhein-Neckar (BioRN) Spitzencluster programs.
30 November 2009•3 mins read
